Despite antiatherogenic metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 3, 2009, Pages 341-347

  MacDonald, Marcia L E ^a   Van Eck, Miranda ^b   Hildebrand, Reeni B ^b   Wong, Brian W C ^c   Bissada, Nagat ^a   Ruddle, Piers ^a   Kontush, Anatol ^d,e   Hussein, Hala ^d,e   Pouladi, Mahmoud A ^a   Chapman, M John ^d,e   Fievet, Catherine ^f,g,h   Van Berkel, Theo J C ^b   Staels, Bart ^f,g,h   McManus, Bruce M ^c   Hayden, Michael R ^a,i  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b LEIDEN UNIVERSITY   (Netherlands)

^c ST PAUL S HOSPITAL   (Canada)

^d Dyslipoproteinemia and Atherosclerosis Research Unit   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f INSTITUT PASTEUR DE LILLE   (France)

^g INSERM   (France)

^h UNIV LILLE   (France)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apolipoproteins; Atherosclerosis; Hyperlipoproteinemia; Inflammation; Lipoproteins

Indexed keywords

ACYL COENZYME A DESATURASE; ACYL COENZYME A DESATURASE 1; AMYLOID A PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; UNCLASSIFIED DRUG; APOLIPOPROTEIN; ARYLDIALKYLPHOSPHATASE; AUTACOID; HIGH DENSITY LIPOPROTEIN; SCD1 PROTEIN, MOUSE; SERUM AMYLOID A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; CIRCULATION; CONTROLLED STUDY; DIET; DISEASE SEVERITY; ENZYME DEFICIENCY; FEMALE; GENE DELETION; HYPERLIPIDEMIA; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PYODERMA GANGRENOSUM; SKIN INFLAMMATION; ANIMAL; BLOOD; C57BL MOUSE; DISEASE COURSE; DISEASE MODEL; ENZYMOLOGY; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE MUTANT; PATHOLOGY; SKIN ULCER; TIME;

ANIMALS; APOLIPOPROTEINS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HYPERLIPIDEMIAS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LIPOPROTEINS, HDL; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, LDL; SERUM AMYLOID A PROTEIN; SKIN ULCER; STEAROYL-COA DESATURASE; TIME FACTORS;

EID: 61549135741     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.181099     Document Type: Article

References (43)

1. Miyazaki M, Ntambi JM. Role of stearoyl-coenzyme A desaturase in lipid metabolism. Prostaglandins Leukot Essent Fatty Acids. 2003;68: 113-121.
2. Miyazaki M, Kim YC, Gray-Keller MP, Attie AD, Ntambi JM. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J Biol Chem. 2000;275:30132-30138.
3. Landau JM, Sekowski A, Hamm MW. Dietary cholesterol and the activity of stearoyl CoA desaturase in rats: evidence for an indirect regulatory effect. Biochim Biophys Acta. 1997;1345:349-357.
4. Man WC, Miyazaki M, Chu K, Ntarnbi J. Colocalization of SCD1 and DGAT2: implying preference for endogenous monounsarurated fatty acids in triglyceride synthesis. J Lipid Res. 2006;47:1928-1939.
5. Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, Song Y, Cohen P, Friedman JM, Attie AD. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A. 2002;99:11482-11486.
6. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, Sharma R, Hudgins LC, Ntambi JM, Friedman JM. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science. 2002; 297:240-243.
7. MacDonald MLE, Singaraja RR, Bissada N, Ruddle P, Watts R, Karasinska JM, Gibson WT, Fievet C, Vance JE, Staels B, Hayden MR. Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. J Lipid Res. 2008;49:217-229.
8. Getz GS, Reardon CA. Diet and murine atherosclerosis. Arteriosder Thromb Vasc Biol. 2006;26:242-249.
9. Zheng Y, Eilertsen KJ, Ge L, Zhang L, Sundberg JP, Prouty SM, Stenn KS, Parimoo S. Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouse. Nat Genet. 1999;23:268-270.
10. Sundberg JP, Boggess D, Sundberg BA, Eilertsen K, Parimoo S, Filippi M, Stenn K. Asebia-2J (Scd1(ab2J)): a new allele and a model for scarring alopecia. Am J Pathol. 2000;156:2067-2075.
11. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotem receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993;92:883-893.
12. Singaraja RR, Fievet C, Castro G, James ER, Hennuyer N, Clee SM, Bissada N, Choy JC, Fruchart J, McManus BM, Staels B, Hayden MR. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest. 2002;110:35-42.
13. Khan-Merchant N, Penumetcha M, Meilhac O, Parthasarathy S. Oxidized fatty acids promote atherosclerosis only in the presence of dietary cholesterol in low-density lipoprotein receptor knockout mice. J Nutr. 2002; 132:3256-3262.
14. Brown WR, Hardy MH. A hypothesis on the cause of chronic epidermal hyperproliferation in asebia mice. Clin Exp Dermatol. 1988;13:74-77.
15. Oran A, Marshall JS, Kondo S, Paglia D, McKenzie RC. Cyclosporin inhibits intercellular adhesion molecule-1 expression and reduces mast cell numbers in the asebia mouse model of chronic skin inflammation. Br J Dermatol. 1997;136:519-526.
16. De Pitá O, Ruffelli M, Cadoni S, Frezzolini A, Biava GF, Simom R, Bottari V, De Sanctis G. Psoriasis: comparison of immunological markers in patients with acute and remission phase. J Dermatol Sci. 1996;13: 118-124.
17. Kowalzick L, Kleinheinz A, Neuber K, Weichenthal M, Köhler I, Ring J. Elevated serum levels of soluble adhesion molecules ICAM-1 and ELAM-1 in patients with severe atopic eczema and influence of UVA1 treatment. Dermatology. 1995;190:14-18.
18. Cooper KD, Hammerberg C, Baadsgaard O, Elder JT, Chan LS, Taylor RS, Voorhees JJ, Fisher G Interleukin-1 in human skin: dysregulation in psoriasis. J Invest Dermatol. 1990;95:24S-26S.
19. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111: 1053-1057.
20. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA. 2003;100:7265-7270.
21. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342-374.
22. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arteriosder Thromb Vasc Biol. 2001;21:473-480.
23. Hardardóttir I, Kunitake ST, Moser AH, Doerrler WT, Rapp JH, Grünfeld C, Feingold KR. Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J Clin Invest. 1994;94:1304-1309.
24. Sun Y, Hao M, Luo Y, Liang CP, Silver DL, Cheng C, Maxfield FR, Tall AR. Stearoyl-CoA desaturase inhibits ATP-binding cassette transporter al-mediated cholesterol efflux and modulates membrane domain structure. J Biol Chem. 2003;278:5813-5820.
25. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sortie PD, Catellier D, Patsch W Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108-1113.
26. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105:2696-2698.
27. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
28. Ridker PM, Rifai N, Stampfer MI, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772.
29. Pradhan AD, Manson JE, Rossouw IE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002;288:980-987.
30. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AMJ, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
31. Nofer J, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EAL. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2007;115: 501-508.
32. Cyrus T, Tang LX, Rokach J, FitzGerald GA, Pratico D. Lipid peroxidation and platelet activation in murine atherosclerosis. Circulation. 2001;104:1940-1945.
33. Lewis KE, Kirk EA, McDonald TO, Wang S, Wight TN, O'Brien KD, Chait A. Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation. 2004;110: 540-545.
34. Attie AD, Krauss RM, Gray-Keller MP, Brownlie A, Miyazaki M, Kastelein JJ, Lusis AJ, Stalenhoef AF, Stoehr JP, Hayden MR, Ntambi JM. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res. 2002;43:1899-1907.
35. Stumvoll M. Control of glycaemia: from molecules to men. Minkowski Lecture 2003. Diabetologia. 2004;47:770-781.
36. Pan DA, Lillioja S, Milner MR, Kriketos AD, Baur LA, Bogardus C, Storlien LH. Skeletal muscle membrane lipid composition is related to adiposity and insulin action. J Clin Invest. 1995;96:2802-2808.
37. Simon JA, Fong J, Bernert JTJ. Serum fatty acids and blood pressure. Hypertension. 1996;27:303-307.
38. Petersson H, Basu S, Cederholm T, Riserus U. Serum fatty acid composition and indices of stearoyl-CoA desaturase activity are associated with systemic inflammation: longitudinal analyses in middle-aged men. Br J Nutr. 2007:1-4.
39. Heffernan AGA. Fatty Acid Composition of Adipose Tissue in Normal and Abnormal Subjects. Am J Clin Nutr. 1964;15:5-10.
40. Gutierrez-Juarez R, Pocai A, Mulas C, Ono H, Bhanot S, Monia BP, Rossetti L. Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J Clin Invest. 2006;116: 1686-1695.
41. Brown JM, Chung S, Sawyer JK, Degirolamo C, Alger HM, Nguyen T, Zhu X, Duong M, Wibley AL, Shah R, Davis MA, Kelley K, Wilson MD, Kent C, Parks JS, Rudel LL. Inhibition of Stearoyl-Coenzyme A Desaturase 1 Dissociates Insulin Resistance and Obesity From Atherosclerosis. Circulation. 2008;118:1467-1475.
42. Savransky V, Jun J, Li J, Nanayakkara A, Fonti S, Moser AB, Steele KE, Schweizer MA, Paul SP, Bhanot S, Schwanz AR, Polotsky VY. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ Res. 2008;103:1173-1180.
43. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 1999;100:1816-1822.